Neovacs S.A. (ALNEV.PA) Stock

About Neovacs S.A.

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNa Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of asthma, dermatomyositis, and all food allergies; and kinoid vaccine that simultaneously targets IL-4 and IL-13 allergies. The company was founded in 1993 and is based in Suresnes, France.

Neovacs S.A. is led by CEO Hugo Brugiere, employs 16 people, headquartered in Suresnes, FR, publicly traded since 2010.

Neovacs S.A. (ALNEV.PA) stock trades at $0.75 with a market capitalization of $35. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.02, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.68 and $9879.00, and currently trades 100.0% below its 52-week high.

On profitability, Neovacs S.A. generates a return on equity (ROE) of -23.23%, an operating margin of -1683.64%, a net profit margin of 0.00%.

Official website: www.neovacs.com